Liver & Bile Duct Cancer Outcomes at KFSYSCC
Between 2015-2019, the five-year survival rate for liver & bile duct cancer at KFSYSCC was 37.8% vs 30.7% for other hospitals in Taiwan..
Basic Information and Distribution of 3,285 Liver and Bile Duct Cancer Patients at KFSYSCC from 1990-2019
| Total | 1990-1994 | 1995-1999 | 2000-2004 | 2005-2009 | 2010-2014 | 2015-2019 | |
|---|---|---|---|---|---|---|---|
| n | 3,285 | 33 (1%) | 363 (11%) | 1,021 (31%) | 727 (22%) | 654 (20%) | 487 (15%) |
| Gender (%) | |||||||
| Male | 2,452 (75%) | 24 (73%) | 285 (79%) | 759 (74%) | 537 (74%) | 481 (74%) | 366 (75%) |
| Female | 833 (25%) | 9 (27%) | 78 (21%) | 262 (26%) | 190 (26%) | 173 (26%) | 121 (25%) |
| Age | |||||||
| Mean/Median | 59/60 | 56/61 | 56/58 | 58/60 | 60/62 | 60/60 | 61/62 |
| Range | 4-94 | 14-82 | 15-85 | 4-89 | 26-94 | 19-90 | 28-93 |
| Q1-Q3 | 51-68 | 43-65 | 48-66 | 49-68 | 52-70 | 52-68 | 54-69 |
| Stage (%) | |||||||
| I | 529 (16%) | 0 (0%) | 8 (2%) | 87 (9%) | 155 (21%) | 176 (27%) | 103 (21%) |
| II | 705 (21%) | 8 (24%) | 61 (17%) | 185 (18%) | 171 (24%) | 176 (27%) | 124 (25%) |
| III | 707 (22%) | 1 (3%) | 16 (4%) | 103 (10%) | 279 (38%) | 156 (24%) | 130 (27%) |
| IV | 851 (26%) | 8 (24%) | 138 (38%) | 368 (36%) | 88 (12%) | 178 (27%) | 115 (24%) |
| Unknown | 493 (15%) | 16 (48%) | 140 (39%) | 278 (27%) | 34 (5%) | 134 (20%) | 15 (3%) |
Based on KFSYSCC's cancer registry from 1990 to 2019, there were 3,285 analytic liver and bile duct cancer cases, with 2,452 males (75%) and 833 females (25%). The average and median ages were 59 and 60 years old, respectively; the youngest patient was 4 years old, and the oldest was 94 years old; the interquartile range (Q1-Q3) was 51-68. By stage, there were 529 stage 1 patients (16%), 705 stage II patients (21%), 707 stage III patients (22%), and 851 stage IV patients (26%). The table below presents the basic patient information and stage distribution, categorized by the year of diagnosis.
Survival Curves for 3,285 Liver and Bile Duct Cancer Patients (1990-2019), Stratified by Year of Diagnosis
From 1990 to 2019, the chart illustrates the five-year observed survival rates for 3,285 liver and bile duct cancer patients at KFSYSCC, stratified by the year of diagnosis. The graph shows the five-year survival rate for liver and bile duct cancer increased from 13% in 1990-1994 to 38% in 2015-2019, while the ten-year survival rate rose from 3% in 1990-1994 to 19% in 2010-2014.
Treatment Methods and Stages for 487 Liver and Bile Duct Cancer
Patients at KFSYSCC (2015-2019)
| Treatment Type | Total | Stage I | Stage II | Stage III | Stage IV | Unknown |
|---|---|---|---|---|---|---|
| Total | 487 | 103 | 124 | 130 | 115 | 15 |
| Surgical Treatment | 169 (35%) | 74 (72%) | 65 (52%) | 17 (13%) | 8 (7%) | 5 (33%) |
| Radiation Therapy | 43 (9%) | 3 (3%) | 4 (3%) | 5 (4%) | 28 (24%) | 3 (20%) |
| Chemotherapy | 292 (60%) | 31 (30%) | 66 (53%) | 108 (83%) | 79 (69%) | 8 (53%) |
| Targeted Therapy | 68 (14%) | 0 (0%) | 3 (2%) | 23 (18%) | 42 (37%) | 0 (0%) |
| Hormone Therapy | 0 (0%) | - | ||||
| Immunotherapy | 7 (1%) | 0 (0%) | 0 (0%) | 3 (2%) | 4 (3%) | 0 (0%) |
| Palliative Care | 68 (14%) | 0 (0%) | 1 (1%) | 18 (14%) | 44 (38%) | 5 (33%) |
| Bone Marrow/Stem Cell Transplant | 0 (0%) | - | ||||
| No Record of Initial Treatment Reported | 3 (1%) | 0 (0%) | 1 (1%) | 1 (1%) | 1 (1%) | 0 (0%) |
Between 2015 and 2019, there were a total of 487 analytic liver and bile duct cancer cases, including 103 patients in stage I, 124 in stage II, 130 in stage III, and 115 in stage IV. In terms of treatment methods, 169 patients (35%) underwent surgical treatment, 43 (9%) received radiation therapy, 292 (60%) underwent chemotherapy, 68 (14%) received targeted therapy, 7 (1%) received immunotherapy, 68 (14%) underwent palliative care, and 3 (1%) had no record of initial treatment reported.
Five-Year Survival Rates of 487 Liver and Bile Duct Cancer Patients by Stage (2015-2019)
KFSYSCC’s 2015-2019 five-year observed survival rates for 487 liver and bile duct cancer patients, stratified by stage, are presented in the following chart. As shown in the graph, the five-year survival rate is 80% for 1, 62% for stage 2, 11% for stage 3, and 7% for stage 4.